Printer Friendly

RXi Pharmaceuticals incurs lower net loss of USD2.0m for Q4 2017.

M2 PHARMA-March 27, 2018-RXi Pharmaceuticals incurs lower net loss of USD2.0m for Q4 2017

(C)2018 M2 COMMUNICATIONS

Biotechnology company RXi Pharmaceuticals Corporation (NASDAQ:RXII) stated on Monday it recorded a net loss applicable to common stockholders of USD2.0m for the fourth quarter ended 31 December 2017.

This is a decrease in net loss applicable to common stockholders when compared with USD4.4m for the quarter ended 31 December 2016. The decrease was due to the one-time charge related to the beneficial conversion feature of the Company's Series B Convertible Preferred Stock in 2016.

Revenues of USD15,000 were generated for the quarter ended 31 December 2017. The company had no revenue during the quarter ended 31 December 2016. The revenues for the quarter were due to the work performed under the grant with BioAxone.

Research and development expense of USD1.2m were recorded for the quarter ended 31 December 2017, a decline from R&D of USD1.3m for the quarter ended 31 December 2016, due to lower spending on clinical trial-related expenses as subject visits in each of the ongoing clinical trials came to an end.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Financial report
Date:Mar 27, 2018
Words:201
Previous Article:Enterin concludes enrolment under Phase 2a RASMET study in Parkinson's Disease.
Next Article:Arena Pharmaceuticals concludes public offering of 9.78m common stock.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters